Drugs / Marketed plasma-derived VWF/FVIII concentrate
Marketed plasma-derived VWF/FVIII concentrate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00816660 Comparator | Dec 2008 → Aug 2010 | von Willebrand disease 3 | Baxalta now part of Shire | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Marketed plasma-derived VWF/FVIII concentrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00816660 ↗ |
| Modality | Protein / enzyme biologic | “The PK of rVWF ristocetin cofactor activity, VWF antigen, and collagen-binding activity were similar to those of the comparator plasma-derived (pd) VWF-pdFVIII.” PMID 23777763 ↗ Jun 2013 |